Whanin Pharm (016580) — Cash Flow-to-Debt Ratio
Whanin Pharm (016580) has a Cash Flow-to-Debt Ratio of 0.16x as of June 2026, meaning its operating cash flow of ₩9.26 Billion could theoretically repay 0% of its total liabilities (₩57.15 Billion) in one year. See Whanin Pharm free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Whanin Pharm Cash Flow-to-Debt Ratio (2009–2025)
Historical debt coverage capacity for Whanin Pharm across 13 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Whanin Pharm.
Annual Cash Flow-to-Debt Ratio for Whanin Pharm (2009–2025)
Year-by-year debt coverage analysis for Whanin Pharm. Check earnings quality score of Whanin Pharm to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.16x | ₩9.04 Billion | ₩57.88 Billion | ▼ -63.2% |
| 2024 | 0.42x | ₩20.69 Billion | ₩48.70 Billion | ▼ -21.2% |
| 2023 | 0.54x | ₩23.20 Billion | ₩43.02 Billion | ▲ +13.4% |
| 2022 | 0.48x | ₩16.85 Billion | ₩35.45 Billion | ▼ -51.6% |
| 2021 | 0.98x | ₩35.32 Billion | ₩35.96 Billion | ▲ +42.2% |
| 2020 | 0.69x | ₩22.75 Billion | ₩32.96 Billion | ▼ -15.1% |
| 2019 | 0.81x | ₩24.73 Billion | ₩30.42 Billion | ▲ +30.9% |
| 2018 | 0.62x | ₩17.45 Billion | ₩28.10 Billion | ▼ -16.0% |
| 2017 | 0.74x | ₩23.48 Billion | ₩31.75 Billion | ▼ -13.0% |
| 2016 | 0.85x | ₩19.82 Billion | ₩23.31 Billion | ▼ -23.9% |
| 2012 | 1.12x | ₩21.11 Billion | ₩18.90 Billion | ▲ +20.1% |
| 2011 | 0.93x | ₩15.12 Billion | ₩16.25 Billion | ▼ -47.5% |
| 2009 | 1.77x | ₩18.61 Billion | ₩10.51 Billion | — |